Downhill running does not alter blood C1q availability or complement-dependent cytotoxicity of therapeutic monoclonal antibodies against haematological cancer cell lines in vitro

Abstract Complement-dependent cytotoxicity (CDC) is a primary mechanism-of-action of monoclonal antibody (mAb) immunotherapies used to treat haematological cancers, including rituximab and daratumumab. However, mAb efficacy may be limited by reduced bioavailability of complement C1q – which activate...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Harrison D. Collier-Bain, Frankie F. Brown, Adam J. Causer, Lois Ross, Daniela Rothschild-Rodriguez, Noah Browne, Rachel Eddy, Kirstie L. Cleary, Juliet C. Gray, Mark S. Cragg, Sally Moore, James Murray, James E. Turner, John P. Campbell
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Portfolio 2024-11-01
coleção:	Scientific Reports
Assuntos:	Complement-dependent cytotoxicity Immunotherapy Exercise Muscle damage Complement C1q
Acesso em linha:	https://doi.org/10.1038/s41598-024-79690-8
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!